Trial Profile

A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG116, ADG116 Combined With Toripalimab (Anti-PD-1 Antibody), ADG116 Combined With ADG106 (Anti-CD137 Antibody) in Patients With Advanced/Metastatic Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADG 106 (Primary) ; ADG 116 (Primary) ; Toripalimab (Primary)
Indications Gynaecological cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; Proof of concept
Sponsors Adagene

07 Nov 2024 According to an Adagene media release, data from this trial will be presented as a poster at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place in Houston, Nov. 6 - 10, 2024.
14 Aug 2024 Planned End Date changed from 15 Aug 2024 to 1 Feb 2025.
30 Jan 2024 Planned End Date changed from 7 Jan 2024 to 15 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com